MX375329B - 2,2,2-trifluoroetil-tiadiazinas. - Google Patents

2,2,2-trifluoroetil-tiadiazinas.

Info

Publication number
MX375329B
MX375329B MX2016016061A MX2016016061A MX375329B MX 375329 B MX375329 B MX 375329B MX 2016016061 A MX2016016061 A MX 2016016061A MX 2016016061 A MX2016016061 A MX 2016016061A MX 375329 B MX375329 B MX 375329B
Authority
MX
Mexico
Prior art keywords
trifluoroetil
thiadiazines
present
alzheimer
therapeutic
Prior art date
Application number
MX2016016061A
Other languages
English (en)
Other versions
MX2016016061A (es
Inventor
Bjoern Bartels
Cosimo Dolente
Jens-Uwe Peters
Lilli Anselm
Mark Rogers-Evans
Thomas Woltering
Sander Ulrike Obst
Wolfgang Guba
Wolfgang Haap
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016016061A publication Critical patent/MX2016016061A/es
Publication of MX375329B publication Critical patent/MX375329B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula (I) que tiene una actividad inhibidora de BACE1, su fabricación, las composiciones farmacéuticas que lo contienen y su uso como substancias terapéuticamente activas. Los compuestos activos de la presente invención son útiles en el tratamiento terapéutico o profiláctico por ejemplo de la enfermedad de Alzheimer.(ver Fórmula).
MX2016016061A 2014-08-15 2015-08-12 2,2,2-trifluoroetil-tiadiazinas. MX375329B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14181123 2014-08-15
PCT/EP2015/068506 WO2016023927A1 (en) 2014-08-15 2015-08-12 2,2,2-trifluoroethyl-thiadiazines

Publications (2)

Publication Number Publication Date
MX2016016061A MX2016016061A (es) 2017-03-10
MX375329B true MX375329B (es) 2025-03-06

Family

ID=51302940

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016061A MX375329B (es) 2014-08-15 2015-08-12 2,2,2-trifluoroetil-tiadiazinas.

Country Status (10)

Country Link
US (1) US9896438B2 (es)
EP (1) EP3180330B1 (es)
JP (1) JP6543697B2 (es)
KR (1) KR20170043581A (es)
CN (1) CN106459006B (es)
BR (1) BR112016026814A8 (es)
CA (1) CA2952160A1 (es)
MX (1) MX375329B (es)
RU (1) RU2692102C2 (es)
WO (1) WO2016023927A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109180672A (zh) * 2018-09-29 2019-01-11 广东东阳光药业有限公司 亚氨基噻二嗪二氧化物衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19500558A1 (de) * 1995-01-11 1996-07-18 Merck Patent Gmbh 3-Alkoxycarbonyl-thiadiazinone
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8557826B2 (en) * 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
WO2014150331A1 (en) * 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use
US9428476B2 (en) * 2013-03-15 2016-08-30 Merck Sharp & Dohme Corp. S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use
MX365292B (es) * 2013-12-20 2019-05-29 Hoffmann La Roche 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.

Also Published As

Publication number Publication date
CN106459006A (zh) 2017-02-22
US20170226091A1 (en) 2017-08-10
EP3180330B1 (en) 2021-03-03
MX2016016061A (es) 2017-03-10
RU2017107495A (ru) 2018-09-17
BR112016026814A2 (pt) 2017-08-15
RU2692102C2 (ru) 2019-06-21
US9896438B2 (en) 2018-02-20
KR20170043581A (ko) 2017-04-21
BR112016026814A8 (pt) 2021-07-20
JP2017524006A (ja) 2017-08-24
RU2017107495A3 (es) 2019-02-25
CN106459006B (zh) 2020-02-11
JP6543697B2 (ja) 2019-07-10
CA2952160A1 (en) 2016-02-18
EP3180330A1 (en) 2017-06-21
WO2016023927A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
PH12015502365A1 (en) Bace1 inhibitors
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
PH12013502156A1 (en) 1,3-oxazines as bace1 and/or bace2 inhibitors
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
EA201990400A1 (ru) Соединения и композиции и их применение
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز
PH12017501668A1 (en) Bace1 inhibitors
MX365292B (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.
EA201990074A1 (ru) Гетероциклические соединения как иммуномодуляторы

Legal Events

Date Code Title Description
FG Grant or registration